Virax Biolabs
VRAX
2 hedge funds and large institutions have $28.6K invested in Virax Biolabs in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.
0.64% less ownership
Funds ownership: 1.45% → 0.81% (-0.64%)
50% less funds holding
Funds holding: 4 → 2 (-2)
60% less capital invested
Capital invested by funds: $71.5K → $28.6K (-$42.9K)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$16.2K |
| 2 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$4.88K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$25.6K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$15.5K |
| 3 |
HF
HRT Financial
New York
|
-$15K |
VRAX Hedge Fund Activity: Q2 2025 in Review
2 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Virax Biolabs (VRAX) for Q2 2025, worth a combined $28.6K — down 60% from $71.5K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of VRAX and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Citadel Advisors, adding an estimated $16.2K. The largest seller was UBS Group, exiting entirely with an estimated $25.6K sold.
- 2 institutional investors held Virax Biolabs (VRAX) as of Q2 2025, down from 4 in Q1 2025.
- Funds reported $28.6K of Virax Biolabs stock for Q2 2025, down 60% quarter-over-quarter.
- 1 fund opened new Virax Biolabs positions in Q2 2025 and 3 closed out, a net change of -2 holders.
- The largest Virax Biolabs buyer in Q2 2025 was Citadel Advisors, an estimated $16.2K added.
- The largest Virax Biolabs seller in Q2 2025 was UBS Group, an estimated $25.6K sold.
Based on aggregated 13F filings for Q2 2025.